Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis - Archive ouverte HAL Access content directly
Journal Articles American Journal of Respiratory and Critical Care Medicine Year : 2020

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

(1) , , (2) , (3) , (4) , (5) , (6) , , (3) , (7) , (8) , , (9) , (10, 11, 12) , (13) , (14) , , (15) , (16) , (17)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Pierre-Régis Burgel
Anne Munck
  • Function : Author
Michele Porzio
  • Function : Author
Julie Macey
  • Function : Author
Clémence Dehillotte
  • Function : Author

Abstract

Rationale: Lumacaftor-ivacaftor is a CFTR (cystic fibrosis transmembrane conductance regulator) modulator combination recently approved for patients with cystic fibrosis (CF) homozygous for the Phe508del mutation.Objectives: To evaluate the safety and effectiveness of lumacaftor-ivacaftor in adolescents (≥12 yr) and adults (≥18 yr) in a real-life postapproval setting.Methods: The study was conducted in the 47 CF reference centers in France. All patients who initiated lumacaftor-ivacaftor from January 1 to December 31, 2016, were eligible. Patients were evaluated for lumacaftor-ivacaftor safety and effectiveness over the first year of treatment following the French CF Learning Society's recommendations.Measurements and Main Results: Among the 845 patients (292 adolescents and 553 adults) who initiated lumacaftor-ivacaftor, 18.2% (154 patients) discontinued treatment, often owing to respiratory (48.1%, 74 patients) or nonrespiratory (27.9%, 43 patients) adverse events. In multivariable logistic regression, factors associated with increased rates of discontinuation included adult age group, percent predicted FEV1 (ppFEV1) less than 40%, and numbers of intravenous antibiotic courses during the year before lumacaftor-ivacaftor initiation. Patients with continuous exposure to lumacaftor-ivacaftor showed an absolute increase in ppFEV1 (+3.67%), an increase in body mass index (+0.73 kg/m2), and a decrease in intravenous antibiotic courses by 35%. Patients who discontinued treatment had significant decrease in ppFEV1, without improvement in body mass index or decrease in intravenous antibiotic courses.Conclusions: Lumacaftor-ivacaftor was associated with improvement in lung disease and nutritional status in patients who tolerated treatment. Adults who discontinued lumacaftor-ivacaftor, often owing to adverse events, were found at high risk of clinical deterioration.
Not file

Dates and versions

hal-02451455 , version 1 (23-01-2020)

Identifiers

Cite

Pierre-Régis Burgel, Anne Munck, Isabelle Durieu, Raphaël Chiron, Laurent Mely, et al.. Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201 (2), pp.188-197. ⟨10.1164/rccm.201906-1227OC⟩. ⟨hal-02451455⟩
39 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More